- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a target name.
BioCentury | May 31, 2024
Distillery Therapeutics
Controlling SPHK1 and SPHK2 activity for heart failure
BioCentury | Sep 16, 2021
Product Development
Quick Takes: FDA approves Takeda’s Exkivity for NSCLC with specific mutation
Plus: an ALS reversal, Theravance downsizing, Calliditas still first in line, EU earmarks €50B for HERA and more
BioCentury | Aug 27, 2021
Translation in Brief
Stanford tech advances RNA structure prediction
Plus: Denali, Editas, Fred Hutchinson and more
BioCentury | Sep 9, 2020
Product Development
COVID-19 roundup: SpyBiotech-Serum Institute of India send HBV-based COVID-19 vaccine to clinic; plus Vaxart, Inovio-Thermo Fisher and RedHill
SpyBiotech, Serum Institute of India start vaccine trialU.K. biotech SpyBiotech Ltd. and its partner the Serum Institute of India on Tuesday started a Phase I/II trial of a virus-like particle
BioCentury | Apr 7, 2020
Product Development
COVID-19 roundup: Inovio starts vaccine trial; plus updates from RedHill, Hope, CytoDyn, Gilead, Takeda, AACR and UNC-Emory
BioCentury is providing this story for free given the urgent need for information about the COVID-19 crisis. For more analysis, sign up for our daily email.
BioCentury | Nov 30, 2018
Clinical News
RedHill's Yeliva yields one partial response in MM patient in preliminary Phase Ib data
Items per page:
1 - 10 of 16